🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:

🔥 OUR LATEST #OriginalResearch in CancerMedicine on Small Cell Neuroendocrine Carcinoma of the Urinary Tract (SCNEC-URO)👉What drives post-surgical relapse in this aggressive disease? Omar Alhalabi, MD Matt Campbell MD, MS MD Anderson Cancer Center 🔗bit.ly/3E3R7lJ A thread🧵1/

The #AUC3 meeting in Miami renal session. Voting on whom gets adjuvant pembrolizumab. Size (T stage) is unlikely to accurately represent biological response to PD-1 therapy, grade maybe better, but we need tissue/circulating biomakers. Toni Choueiri, MD Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO

📢🚨 Hot off the press The Lancet Oncology for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc

Evidence continues to emerge that CD4 T cells are important for cancer vaccines. New study in human renal cancer shows that >90% of T cells generated by cancer vaccine are CD4, not CD8. nature.com/articles/s4158…

🌟Comprehensive analysis of targetable mutations & tumor microenvironment in urachal cancer 🔬🧬🌟 OncoAlert nature.com/articles/s4169… 🔹 Authors: David J. Benjamin, Tolulope T. Adeyelure, Andrew Elliott, Sourat Darabi, Thomas Lee, Rana McKay, MD, FASCO, Matthew J. Oberley & Arash

Andy Hahn Andrew Johns, MD Elizabeth Plimack MD Cristiane D Bergerot Nazli Dizman Bradley McGregor Linghua Wang, MD, PhD Rahul Sheth Michael Serzan, MD Katie Coleman Giannicola Genovese MD, PhD Omar Alhalabi, MD Luigi Perelli Jeffrey Graham Chad Tang, MD Salvatore La Rosa Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Daniel Shapiro Qing Zhang Dan George Priya Rao, MD Ashish M. Kamat, MD, MBBS Brian F. Chapin ROHIT MEHRA Lisa Henske Daniel Heng Eleonora Dondossola,PhD Daniel E. Frigo, Ph.D. Samson W. Fine, MD Katy Beckermann 5/5 This study establishes CA-125 as a clinically relevant biomarker for RMC, enabling non-invasive disease monitoring. Future directions include exploring MUC16-targeted therapies, and combiningCA-125 with ctDNA for precision tracking. #endRMC #CancerBreakthroughs

GU Research Digest for the week of February 15 - 21: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

China Out-Licensing Deals (YTD 2025) 16 deals for innovative drugs so far, mostly by US-based companies targeting early stage antibody-based therapeutics within I&I and oncology Some thoughts on how we got here and where this is headed:

📢 12-year outcomes of cystectomies in NMIBC 🔹 Upstaging: pT2 (12.68%), pT3 (8.2%), pT4 (4.2%), pN+ (8.2%) 🔹 OS: 49%, CSS: 76% 🔹 1:4 patients upstaged to>pT2 Biggest takeaway here … understaging of NMIBC is wild❗️ bjui-journals.onlinelibrary.wiley.com/doi/full/10.11… #BladderCancer #CancerResearch

💫🌟🔬 Prognostic Gene Expression Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC)🌟💫 Authors: M.N. Sharifi & al. OncoAlert 📊 Key Findings: ✅ Identified 5 prognostic gene expression clusters. ✅ Loss of AR signaling, high cell proliferation, and

Largest study of BRCA-associated cancers (24,309) shows that somatic tumor landscape is influenced by germline HRR muts: gBRCA1-altered cancers are enriched in somatic TP53 muts; gATM-altered cancers are depleted in TP53 mut. Congrats Ali Arafa @umncancer aacrjournals.org/clincancerres/…

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 nirm DrBagrodia  Dr #EzraBaraban Yale Pathology Christian D. Fankhauser Yasserged JAMA OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases

💫🌟🔬 Unraveling the Genetic Landscape of Testicular Germ Cell Tumors (TGCT)! 🧬🌟💫 ❗️Largest whole-exome meta-analysis in TGCT to date sheds light on genetic predisposition in 1,435 cases vs. 18,284 controls. #ZeidKuzbari Charlie Rowlands #IsaacWade #AliceGarrett Chey Loveday

Dr Hikmat Al-Ahmadie highlights markers in #urothelialcarcinoma which may be therapeutically targeted including MMRd/MSI, FGFR3, and antibody-drug conjugate (ADC) markers such as NECTIN-4 and HER2 #gupath GU Pathology Society (GUPS) #USCAP2025

What this means? In patients staged with PSMA-PET and treated with Augmented/intensified WPRT RT, the incremental benefit of adding abiraterone may be modest We hope this adds nuance to personalising Rx for HR Ca Prostate—balancing benefit, cost, access, and toxicity.

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

🚨 #ASCO25 plenary NIVOPOSTOP: 1st DFS win in 20+ yrs for resected high-risk LA-SCCHN ➡️ n=666, NIVO + CRT vs CRT alone 🎉 3-yr DFS: 63.1% vs 52.5% 💥HR 0.76 (p=0.034) ⚠️ mild Gr4 AEs ⬆️ w/ NIVO (13.1% vs 5.6%) ✅ New adjuvant IO standard emerging? #hnscc #Immunotherapy #RadOnc

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

What a great summary on treatment of #Oligometastatic #ProstateCancer ! Congrats Vedang Murthy Maneesh Singh Piet Ost Good learning for every Resident and Senior Faculty! 💪🏻💪🏻